|
07 Apr 2025 |
Bayer Cropscience
|
Consensus Share Price Target
|
4700.35 |
5470.83 |
- |
16.39 |
buy
|
|
|
|
|
24 May 2017
|
Bayer Cropscience
|
Emkay
|
4700.35
|
4625.00
|
4445.20
(5.74%)
|
Target met |
Hold
|
|
|
Bayer reported a sharp 50% yoy drop in revenues to Rs2.4bn and below our estimate of Rs4.7bn (after adjusting for Ind-AS) and is also below consensus estimates. Revenue was impacted due to weak season in South India which constitutes 65% of Q4 sales Gross margins improved 430bps yoy to 44.6% benefiting from lower RM cost. However, Company reported EBITDA loss of Rs581mn vs. a profit of Rs 205mn in Q4FY16 Loss at...
|
|
17 Feb 2017
|
Bayer Cropscience
|
Axis Direct
|
4700.35
|
4050.00
|
4008.00
(17.27%)
|
Target met |
Hold
|
|
|
Bayer's management expects CY17 to be a challenging year due to lower reservoir levels, high channel inventories and poor farmer liquidity;however, firm commodity prices and one goodagri-seasonare sufficient to address these issues. Despite challenges, Bayer's domestic revenue grew 16% YoY in 9M..
|
|
24 Sep 2015
|
Bayer Cropscience
|
Karvy
|
4700.35
|
3322.00
|
3722.75
(26.26%)
|
Target met |
Sell
|
|
|
Increasing proportion of manufactured goods in the overall revenue from 43%in FY15 to 44% in FY17E is expected to lead to a 20 basis points jump in grossmargins from 64.8% in FY15 to 65.0% in FY16E & FY17E. It could have been higher, if not for the weak macro-industry environment. This increase is expected to act as a cushion for the EBITDA margins going forward. But, significant dependence on traded goods will continue to act as a ceiling for margins. We expect EBITDA margins to remain stable at lower levels of 11.9% & 12.3% in FY16E & FY17E respectively.
|